Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589952 | 1.00 | NR3C1 (0.60) | NR3C1ROCK2ROCK1MAPK1DDR1 | |
| SCHEMBL3599882 | 1.00 | NR3C1 (0.60) | NR3C1ROCK2ROCK1MAPK1DDR1 | |
| SCHEMBL14196190 | 0.89 | NR3C1 (0.49) | NR3C1ROCK2ROCK1MAPK1PGR | |
| SCHEMBL9913404 | 0.80 | NR3C1 (0.60) | NR3C1ROCK2ROCK1MAPK1PGR | |
| SCHEMBL3589958 | 0.80 | NR3C1 (0.60) | NR3C1ROCK2ROCK1MAPK1PGR | |
| SCHEMBL3589960 | 0.80 | NR3C1 (0.60) | NR3C1ROCK2ROCK1MAPK1PGR | |
| SCHEMBL3586192 | 0.80 | NR3C1 (0.75) | NR3C1MAPK1PGR | |
| SCHEMBL3586189 | 0.80 | NR3C1 (0.75) | NR3C1MAPK1PGR | |
| SCHEMBL3589077 | 0.78 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL3589072 | 0.78 | NR3C1 (0.72) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198311-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NR0B1, NFKB2 | NR3C1 5/4885ROCK2 3522/4885ROCK1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.